Cancer can begin anywhere in the body and unfortunately it’s not a single disease. Some cancers can spread rapidly while others grow at a slower rate. They also respond to treatment in different ways. There is no easy answer.
It is estimated that there will be approximately 1.7 million new cases of cancer diagnosed in 2018. For men, the most prevalent type of cancer is prostate while for women breast cancer is number one. For both men and women, lung and colorectal cancer are the second and third most common. Current data from the American Cancer Society suggests that the average person’s probability of developing cancer, at any site, is about 1 in 3.
Cancer is predicted to be the cause of death in over half a million (609,640) people in 2018. Lung cancer is the leading cause of all cancer deaths for both men and women even though it is only the second most common in both groups. The mortality rate for other cancers is much lower but still significant. The good news is that survival rates are improving, largely due to earlier detection and advances made in treatment. Overall survival rates have improved 20% from what they were in 1977 (49%) to 2013 (69%).
With so much of the world’s population affected by cancer, we must turn our attention to solutions for both prevention and treatment. Oncology is one of ProTrials primary focuses. Over 90% of our staff have worked on the front lines of these important trials. Our attention has been in all phases of study – I, II, III, Pivotal and Post-Approval – and in many indications. We want to find answers and help stop cancer in its tracks.
of all staff with Oncology Experience
Includes Regional Monitoring, Program and Project Management, Drug Monitoring, Medical Monitoring, Quality Assurance, Data Management, Vendor Management, Site Recruitment, and Clinical Trial Assistance
projects conducted to date